SGK1 inhibitor reverses hyperglycemia partly through decreasing glucose absorption

Journal of Molecular Endocrinology

Volumn 56, Issue 4, 2016, Pages 301-309

  Li, Ping ^a   Hao, Yan ^a   Pan, Feng Hui ^a   Zhang, Min ^a   Ma, Jian Qiang ^a   Zhu, Da Long ^a  

^a THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

Author keywords

IEC 6 intestinal cells; Serum and glucocorticoid inducible kinase 1 (SGK1); Small intestine; Sodium glucose cotransporter 1 (SGLT1)

Indexed keywords

ANTIDIABETIC AGENT; BETA ACTIN; CHOLESTEROL; DEXAMETHASONE; EMD 638683; GLUCOSE; HEMOGLOBIN A1C; MESSENGER RNA; PROTEIN SERINE THREONINE KINASE INHIBITOR; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SODIUM GLUCOSE COTRANSPORTER 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; IMMEDIATE EARLY PROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; SERUM-GLUCOCORTICOID REGULATED KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HEMOGLOBIN BLOOD LEVEL; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INTESTINE BRUSH BORDER; MALE; METABOLIC DISORDER; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL INTESTINE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; DISEASE MODEL; DRUG EFFECTS; INTESTINE ABSORPTION; INTESTINE MUCOSA; METABOLISM; TRANSGENIC MOUSE;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; CELL LINE; DISEASE MODELS, ANIMAL; GLUCOSE; HYPERGLYCEMIA; IMMEDIATE-EARLY PROTEINS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; MALE; MICE; MICE, TRANSGENIC; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RATS;

EID: 85006733634     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-15-0285     Document Type: Article

References (25)

1. Ackermann TF, Boini KM, Beier N, Scholz W, Fuchß T and Lang F 2011 EMD638683, a novel SGK inhibitor with antihypertensive potency. Cellular Physiology and Biochemistry 28 137-146. (doi:10.1159/000331722)
2. Borst O, Schmidt EM, Münzer P, Schönberger T, Towhid ST, Elvers M, Leibrock C, Schmid E, Eylenstein A, Kuhl D, et al. 2012 The serumand glucocorticoid-inducible kinase 1 (SGK1) influences platelet calcium signaling and function by regulation of Orai1 expression in megakaryocytes. Blood 119 251-261. (doi:10.1182/blood-2011-06-359976)
3. Busjahn A, Aydin A, Uhlmann R, Krasko C, Bähring S, Szelestei T, Feng Y, Dahm S, Sharma AM, Luft FC, et al. 2002 Serum- and glucocorticoid-regulated kinase (SGK1) gene and blood pressure. Hypertension 40 256-260. (doi:10.1161/01.HYP.0000030153.19366.26)
4. D’Antona L, Amato R, Talarico C, Ortuso F, Menniti M, Dattilo V, Iuliano R, Gigliotti F, Artese A, Costa G, et al. 2015 SI113, a specific inhibitor of the Sgk1 kinase activity that counteracts cancer cell proliferation. Cellular Physiology and Biochemistry 35 2006-2018. (doi:10.1159/000374008)
5. Das S, Aiba T, Rosenberg M, Hessler K, Xiao C, Quintero PA, Ottaviano FG, Knight AC, Graham EL, Boström P, et al. 2012 Pathological role of serum- and glucocorticoid-regulated kinase 1 in adverse ventricular remodeling. Circulation 126 2208-2219. (doi:10.1161/CIRCULATIONAHA.112.115592)
6. Dieter M, Palmada M, Rajamanickam J, Aydin A, Busjahn A, Boehmer C, Luft FC and Lang F 2004 Regulation of glucose transporter SGLT1 by ubiquitin ligase Nedd4-2 and kinases SGK1, SGK3, and PKB. Obesity Research 12 862-870. (doi:10.1038/oby.2004.104)
7. Di Pietro N, Panel V, Hayes S, Bagattin A, Meruvr S, Pandolfi A, Hugendubler L, Fejes-Tó th G, Naray-Fejes-Tóth A and Mueller E 2010 Serum- and glucocorticoid-inducible kinase 1(SGK1) regulates adipocyte differentiation via forkhead box O1. Molecular Endocrinology 24 370-380. (doi:10.1210/me.2009-0265)
8. Fujita Y, Kojima H, Hidaks H, Fujimiya M, Kashiwagi A and Kikkawa R 1998 Increased intestinal glucose absorption and postprandial hyperglycaemia at the early step of glucose intolerance in Otsuka Long-Evans Tokushima Fatty Rats. Diabetologia 41 1459-1466. (doi:10.1007/s001250051092)
9. Geer EB, Islam J and Buettner C 2014 Mechanisms of glucocorticoidinduced insulin resistance. Focus on adipose tissue function and lipid metabolism. Endocrinology and Metabolism Clinics of North America 43 75-102. (doi:10.1016/j.ecl.2013.10.005)
10. Grahammer F, Henke G, Sandu C, Rexhepaj R, Hussain A, Friedrich B, Risler T, Metzger M, Just L, Skutella T, et al. 2006 Intestinal function of gene-targeted mice lacking serum-and glucocorticoid-inducible kinase 1. American Journal of Physiology: Gastrointestinal and Liver Physiology 290 G1114-G1123. (doi:10.1152/ajpgi.00231.2005)
11. Hall BA, Kim TY, Skor MN and Conzen SD 2012 Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression. Breast Cancer Research and Treatment 135 469-479. (doi:10.1007/s10549-012-2161-y)
12. Kessler M, Acuto O, Storelli C, Murer H, Muller H and Semenze G 1978 A modified procedure for the rapid preparation of efficiently transporting vesicles from small intestinal brush border membranes: their use in investigating some properties of D-glucose and choline transport systems. Biochimica et Biophysica Acta 506 136-154. (doi:10.1016/0005-2736(78)90440-6)
13. Lang F and Voelkl J 2013 Therapeutic potential of serum and glucocorticoid inducible kinase inhibition. Expert Opinion on Investigational Drugs 22 701-714. (doi:10.1517/13543784.2013.778971)
14. Lang F, Böhmer C, Palmada M, Seebohm G, Strutz-seebohm N and Vallon V 2006 (Patho)physiological significance of the serum-and glucocorticoid-inducible kinase isoforms. Physiological Reviews 86 1151-1178. (doi:10.1152/physrev.00050.2005)
15. Lang F, Gorlach A and Vallon V 2009 Targeting SGK1 in diabetes. Expert Opinion on Therapeutic Targets 13 1303-1311. (doi:10.1517/14728220903260807)
16. Li P, Pan FH, Hao Y, Feng WH, Song HD and Zhu DL 2013 SGK1 is regulated by metabolic-related factors in 3T3-L1 adipocytes and overexpressed in the adipose tissue of subjects with obesity and diabetes. Diabetes Research and Clinical Practice 102 35-42. (doi:10.1016/j.diabres.2013.08.009)
17. Oguma T, Nakayama K, Kuriyama C, Matsushita Y, Yoshida K, Hikida K, Obokata N, Tsuda-Tsukimoto M, Saito A, Arakawa K, et al. 2015 Intestinal sodium glucose cotransporter 1 inhibition enhances glucagon-like peptide-1 secretion in normal and diabetic rodents. Journal of Pharmacology and Experimental Therapeutics 354 279-289. (doi:10.1124/jpet.115.225508)
18. Salker MS, Christian M, Steel JH, Nautiyal J, Lavery S, Trew G, Webster Z, Al-Sabbagh M, Puchchakayala G, Föller M, et al. 2011 Deregulation of the serum- and glucocorticoid-inducible kinase SGK1 in the endometrium causes reproductive failure. Natural Medicine 17 1509-1513. (doi:10.1038/nm.2498)
19. Schwab M, Lupescu A, Mota M, Mota E, Frey A, Simon P, Mertens PR, Floege J, Luft F, Asante-Poku S, et al. 2008 Association of SGK1 gene polymorphisms with type 2 diabetes. Cellular Physiology and Biochemistry 21 151-160. (doi:10.1159/000113757)
20. Towhid ST, Liu GL, Ackermann TF, Beier N, Scholz W, Fuchß T, Toulany M, Rodemann HP and Lang F 2013 Inhibition of colonic tumor growth by the selective SGK inhibitor EMD638683. Cellular Physiology and Biochemistry 32 838-848. (doi:10.1159/000354486)
21. Ullrich S, Berchtold S, Ranta F, Seebohm G, Henke G, Lupescu A, Mack AF, Chao CM, Su J, Nitschke R, et al. 2005 Serum-and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoidinduced inhibition of insulin secretion. Diabetes 54 1090-1099. (doi:10.2337/diabetes.54.4.1090)
22. von Wowern F, Berglund G, Carlson J, Månsson H, Hedblad B and Melander O 2005 Genetic variance of SGK-1 is associated with blood pressure, blood pressure change over time and strength of the insulin-diastolic blood pressure relationship. Kidney International 68 2164-2172. (doi:10.1111/j.1523-1755.2005.00672.x)
23. Wagman AS and Nuss JM 2001 Current therapies and emerging targets for the treatment of diabetes. Current Pharmaceutical Design 7 417-450. (doi:10.2174/1381612013397915)
24. Webster MK, Goya L, Ge Y, Maiyar AC and Firestone GL 1993 Characterization of sgk, a novel member of the serine/threonine protein kinase gene family which is transcriptionally induced by glucocorticoids and serum. Molecular and Cellular Biology 13 2031-2040. (doi:10.1128/MCB.13.4.2031)
25. Zhang WY, Lee JJ, Kim IS, Kim Y, Park JS and Myung CS 2010 7-O-Methylaromadendrin stimulates glucose uptake and improves insulin resistance in vitro. Biological and Pharmaceutical Bulletin 33 1494-1499. (doi:10.1248/bpb.33.1494)